findmyKOL
Clinical trialNCT07689851RecruitingPhase 2Interventional

Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

SponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesEnrollment60Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Gastric Cancer is one of the leading causes of cancer-related death worldwide, and patients with unresectable locally advanced or metastatic disease have a poor prognosis. This study aims to evaluate the safety and efficacy of radiotherapy combined with CAPOX and SHR-1701, a PD-L1/TGF-β bispecific antibody, in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. By improving local tumor control and enhancing systemic antitumor activity, this study seeks to increase the opportunity for curative-intent resection and improve survival outcomes in patients with advance gastric cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Hospital

    Shenzhen, Guangdong, China

    Recruiting
  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

    Recruiting
  • National Cancer Center/cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, China

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

COPOXSHR-1701
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jul 2026
Primary completion
30 Jul 2028
Completion
30 Jul 2029
Last update posted
8 Jul 2026
Registered enrollment
60
Registry id
NCT07689851
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.